Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New dengue drug trial aims to shorten illness and lower virus levels

NCT ID NCT07576868

Disease control Sponsor: Hyundai Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests a new medicine called CP-COV03 in adults with dengue fever. The goal is to see if it can safely lower the amount of virus in the blood and help people feel better faster. About 210 participants will receive either the drug or a placebo. The trial is currently recruiting.

Why investors are watching

Hyundai Bioscience, a micro-cap company, is running a Phase 2/3 trial of its drug CP-COV03 in 210 adult dengue patients. For a company this small, this readout is a major event because a positive result could validate its drug platform and lead to regulatory progress, while a failure would be a serious setback.

If it works: If the trial shows CP-COV03 is safe and effective against dengue, Hyundai Bioscience could gain a marketable treatment for a disease with no specific antiviral therapy. That outcome might attract partners or licensing deals, which would be a meaningful step for a company of its size.

If it fails: Clinical trials often fail, and this one could show the drug does not work or has safety problems. A negative or delayed result would likely hurt the company's prospects and could make it harder to raise future funding.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 210 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who are 18 years or over of age at time of screening. * Patients who have at least two symptoms with a score of 2 or higher within 72 h from fever onset. * Patients who are diagnosed with dengue by NS1 positive (Phase 2- Part 1 only). And patients who are classified as dengue, zika, influenza, COVID-19 and others (Phase 3- Part 2 only) Exclusion Criteria: * Patients who show severe dengue (WHO dengue guideline C, any severe symptoms or clinical laboratory results) * Patients who have previously received dengue vaccine * Patients who have chronic medical conditions such as uncontrolled diabetes mellitus, severe asthma requiring oral steroids or admission to the hospital in the previous 6 months for cardiac disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dengue are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dengue disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dengue

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    2 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • The National Hospital of Tropical Diseases (NHTD)

    RECRUITING

    Hanoi, Vietnam

  • Tien Giang Provincial General Hospital

    RECRUITING

    Mỹ Tho, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.